Compare Freshworks Inc (FRSH) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freshworks Inc vs GSK plc — how do they compare? Freshworks Inc trades at $13.9 (market cap $3.56B), while GSK plc trades at $46.52 (market cap $91.88B). The key difference: GSK plc is far larger — about 25.8× Freshworks Inc's market cap, and GSK plc pays a 3.9% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Freshworks Inc for 39 Days and GSK plc for 93 Days on average.
| FRSH | GSK | |
|---|---|---|
Market Cap | $3.56B | $91.88B |
Volume | 9,066,454 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $13.92 | $61.18 |
52-Week Low | $6.88 | $43.24 |
Typical Hold Time | 39 Days | 93 Days |
Enterprise Value | $2.93B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Freshworks (FRSH) trades at $13.92, up 2.35% today, with strong technical momentum and bullish moving averages. The company achieved its first GAAP profitability in Q2 2026, beating earnings expectations with $0.17 EPS versus $0.13 expected. Revenue growth remains robust at 16% year-over-year, while valuation metrics show a P/E of 21.63 and P/S of 4.28. Recent developments include FedRAMP certification progress and leadership appointments.
The outlook appears positive with analyst consensus at $14.60 price target and 50% buy ratings. Key opportunities include AI monetization and enterprise growth, while risks involve competitive SaaS market pressure and the need to sustain recent profitability gains amid ongoing investments.
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
